Delta Opioid Receptors in the Smell Center Stimulate Cell Signaling Instead of Inhibiting It

Delta opioid receptors in the rat olfactory bulb stimulate (rather than inhibit) adenylate cyclase, with deltorphin I being the most potent agonist at EC50 of 6.7 nM.

Olianas, M C et al.·Molecular pharmacology·1992·Preliminary Evidencein-vitro
RPEP-00242In VitroPreliminary Evidence1992RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Delta opioid receptors primarily mediate adenylate cyclase stimulation in olfactory bulb. Deltorphin I EC50 = 6.7 nM. Mu receptors contribute. Kappa receptors inactive.

Key Numbers

How They Did This

Rat olfactory bulb homogenates treated with selective opioid agonists and antagonists. Adenylate cyclase activity measured. Concentration-response curves and antagonist profiles determined.

Why This Research Matters

Identifying the specific receptor (delta) responsible for unusual stimulatory opioid signaling helps explain how the same receptor family can produce opposite effects in different brain regions.

The Bigger Picture

This shows opioid receptors aren't one-trick ponies. The same receptor type can produce opposite effects depending on where in the brain it's located. This flexibility makes the opioid system far more versatile — and drug design more challenging.

What This Study Doesn't Tell Us

In vitro tissue homogenate study. Cannot identify the specific cell types responsible. The G-protein coupling mechanism for stimulation was not fully characterized.

Questions This Raises

  • ?Why do delta receptors stimulate rather than inhibit signaling in the olfactory bulb?
  • ?Do opioids affect the sense of smell through this mechanism?

Trust & Context

Key Stat:
EC50 = 6.7 nM Deltorphin I was an extremely potent stimulator of adenylate cyclase through delta opioid receptors in the olfactory bulb
Evidence Grade:
Preliminary — in vitro tissue homogenate study providing clear pharmacological characterization but not identifying specific cell types or in vivo relevance.
Study Age:
Published in 1992 (34 years ago). Stimulatory opioid signaling is now recognized as a real phenomenon in specific brain regions.
Original Title:
Characterization of opioid receptors mediating stimulation of adenylate cyclase activity in rat olfactory bulb.
Published In:
Molecular pharmacology, 42(1), 109-15 (1992)
Authors:
Olianas, M C(2), Onali, P(2)
Database ID:
RPEP-00242

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

How can the same receptor do opposite things?

Opioid receptors can couple to different intracellular signaling proteins (G-proteins) depending on the cell type and brain region. In most places they inhibit signaling, but in the olfactory bulb they connect to stimulatory pathways instead.

Does this affect how we smell?

Potentially. If delta opioid receptors actively regulate signaling in the smell center, opioid drugs or natural endorphins could modify olfactory processing — though this hasn't been directly tested in behavioral studies.

Read More on RethinkPeptides

Cite This Study

RPEP-00242·https://rethinkpeptides.com/research/RPEP-00242

APA

Olianas, M C; Onali, P. (1992). Characterization of opioid receptors mediating stimulation of adenylate cyclase activity in rat olfactory bulb.. Molecular pharmacology, 42(1), 109-15.

MLA

Olianas, M C, et al. "Characterization of opioid receptors mediating stimulation of adenylate cyclase activity in rat olfactory bulb.." Molecular pharmacology, 1992.

RethinkPeptides

RethinkPeptides Research Database. "Characterization of opioid receptors mediating stimulation o..." RPEP-00242. Retrieved from https://rethinkpeptides.com/research/olianas-1992-characterization-of-opioid-receptors

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.